Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:42:14.032Z.
Calculation as of: 2026-10-06T19:42:14.032Z.
Quote observation: 2026-10-06T19:40:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Kyverna Therapeutics, Inc.
Market Cap
$373.29M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$375.21M
EV/EBITDA Ratio
N/A
TTM Avg
682.46x
3Y Avg
682.46x
5Y Avg
682.46x
Market Cap
$375.26M
EV/EBITDA Ratio
N/A
TTM Avg
10.71x
3Y Avg
10.71x
5Y Avg
10.71x
Market Cap
$380.77M
EV/EBITDA Ratio
4.28x
TTM Avg
129.81x
3Y Avg
151.06x
5Y Avg
73.64x
Market Cap
$358.85M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$357.10M
EV/EBITDA Ratio
N/A
TTM Avg
40.38x
3Y Avg
40.38x
5Y Avg
40.38x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $373.29M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $375.21M | N/A | 682.46x | 682.46x | 682.46x |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $375.26M | N/A | 10.71x | 10.71x | 10.71x |
| Orthofix Medical Inc. (OFIX)vs › | $380.77M | 4.28x | 129.81x | 151.06x | 73.64x |
| Zura Bio Limited (ZURA)vs › | $382.07M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $360.95M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $387.21M | N/A | 7.49x | 7.49x | 18.24x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $358.85M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.10M | N/A | 40.38x | 40.38x | 40.38x |
| Viemed Healthcare, Inc. (VMD)vs › | $354.03M | 6.48x | 7.04x | 7.63x | 8.90x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
